Dr. Merola is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6000 Harry Hines Blvd
Dallas, TX 75235Phone+1 214-645-2373
Summary
- Joseph F. Merola, MD, MMSc the Chair of Dermatology at UT Southwestern Medical Center in Dallas, TX; he is Professor of Dermatology and Professor of Medicine and Rheumatology. He holds the Mary Kay Distinguished Chair in Dermatology. Previously, Dr. Merola was Vice Chair of Dermatology and Associate Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School in Boston, Massachusetts. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology. He serves as the Vice Chair for Clinical Trials and Innovation, the Director of the Clinical Unit for Research Innovation and Trials (CUReIT), Director of the Center for Skin and Related Musculoskeletal Diseases and the Associate Program Director for the Harvard Combined Internal Medicine-Dermatology Residency Training Program at the Brigham and Women’s Hospital in Boston. Dr. Merola earned his medical degree at the New York University School of Medicine and his Masters of Medical Sciences degree at Harvard Medical School. He completed an internship in Internal Medicine at the Hospital of the University of Pennsylvania in Philadelphia, followed by a residency in Dermatology at the New York University Medical Center, where he was chief resident. He continued with a residency in Internal Medicine and a fellowship in Rheumatology at the Brigham and Women’s Hospital in Boston.
Dr. Merola is Founding President of the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN), the Scientific and Medical Boards of the National Psoriasis Foundation, Board of the International Dermatology Outcome Measures Group and VP of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), Medical and Scientific Board of the Lupus Foundation. He is also the current president of the Medical Dermatology Society and ores-elect of Rheum-Derm Society.
Education & Training
- Harvard Medical SchoolMMSc, Clinical Research, Clinical Scholars Program, 2011
- Brigham and Women's HospitalFellowship, Rheumatology, 2010 - 2013
- Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2010
- NYU Grossman School of MedicineChief Residency, Dermatology, 2008 - 2009
- NYU Grossman School of MedicineResidency, Dermatology, 2006 - 2009
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2005 - 2006
- New York University School of MedicineClass of 2005
Certifications & Licensure
- MA State Medical License 2009 - 2026
- TX State Medical License 2023 - 2026
- FL State Medical License 2021 - 2024
- NH State Medical License 2022 - 2024
- RI State Medical License 2021 - 2024
- VT State Medical License 2022 - 2024
- CT State Medical License 2021 - 2023
- American Board of Dermatology Dermatology
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
- Join now to see all
Clinical Trials
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
Publications & Presentations
PubMed
- Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPI...Joseph F Merola, Albert S Chiou, Emmanuel During, Peter Foley, Jiangming Wu
Journal of the American Academy of Dermatology. 2024-12-01 - 1 citationsEfficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomiz...Joseph F Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla
The Journal of Dermatological Treatment. 2024-12-01 - Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.Joseph F Merola, Alice B Gottlieb, Andreas Pinter, Boni Elewski, Melinda Gooderham
Dermatology and Therapy. 2024-12-01
Journal Articles
- Are Your Patients Satisfied? A Systematic Review of Treatment Satisfaction Measures in PsoriasisSanminder Singh, Alice B Gottlieb, Nicole Salame, Joseph F Merola, Dermatology
- Inflammatory Arthritis and Crystal Arthropathy: Current Concepts of Skin and Systemic ManifestationsJoseph F Merola, Mahdieh Fazel, ScienceDirect
- Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the National Psoriasis FoundationRonald Prussick, Johann E Gudjonsson, Alice Gottlieb, John Koo, Jerry Bagel, Adam R Ford, Joseph A Markenson, Wilson Liao, Joseph F Merola, Jashin J Wu, JAMA
Press Mentions
- UCB Announces U.S. FDA Approvals for BIMZELX® (Bimekizumab-Bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing SpondylitisSeptember 23rd, 2024
- Perspectives on Nonmedical Switching and the COVID-19 Pandemic: A Narrative ReviewNovember 1st, 2022
- Bimekizumab Calms Psoriatic Arthritis in Phase 3 'BE' TrialsJune 15th, 2022
- Join now to see all
Professional Memberships
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: